Garofalo Health Care SpA

Garofalo Health Care SpA maintains a liquidity position with a current ratio of 1.23, indicating a moderate ability to meet short-term obligations, while its debt-to-equity ratio of 0.67 suggests a relatively balanced capital structure. The company's free cash flow of 10.33 million EUR and operating cash flow of 49.04 million EUR support its liquidity, although its cash and equivalents are limited to 310,000 EUR. In terms of profitability, the company's return on equity of 6.91% and return on assets of 2.72% indicate that it is generating returns, albeit at a moderate level compared to industry benchmarks. The operating income of 45.15 million EUR and net income of 23.41 million EUR reflect a solid performance, but the gross profit margin of 45.4% suggests there is room for improvement in cost management. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, making it difficult to assess the risk associated with specific regions or product lines. However, the company's primary focus on pharmaceuticals and healthcare services implies a diversified exposure to the healthcare market. Looking at the growth trajectory, the company's capital expenditure of -33.54 million EUR indicates a reduction in investment, which may signal a strategic shift or a focus on cost optimization. The absence of detailed outlook data for the current and next fiscal years limits the ability to forecast future growth accurately. The risk assessment highlights a medium liquidity risk and a low dilution risk, with the key flag being the negative net cash position after accounting for total debt. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. Recent events and filings do not provide specific details on the company's operations or strategic initiatives, as the available data does not include recent transcripts or filings. Analysts have provided a mean price target of 5.90 EUR with a strong buy recommendation, indicating a positive outlook despite the limited data on recent company developments.